Cynata Therapeutics

Ross Macdonald, Ph.D., CEO

Melbourne, Australia

(ASX: CYP)

Virtual Presentation

Cynata Therapeutics is an Australian clinical-stage stem cell and regenerative medicine company developing a therapeutic mesenchymal stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of multi-donor derived MSCs for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale. Cymerus utilises induced pluripotent stem cells to produce MSCs through a proprietary process that is independent of donor limitations providing an off-the-shelf stem cell platform for therapeutic product manufacture. A successful world-first clinical trial in GvHD has been completed, meeting all safety and efficacy endpoints. The company has commenced a Phase III clinical trial in osteoarthritis and a Phase II trial in respiratory distress with additional trials being planned for 2021/2022.
www.cynata.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions